ZA200209265B - Antithrombotic agents. - Google Patents

Antithrombotic agents.

Info

Publication number
ZA200209265B
ZA200209265B ZA200209265A ZA200209265A ZA200209265B ZA 200209265 B ZA200209265 B ZA 200209265B ZA 200209265 A ZA200209265 A ZA 200209265A ZA 200209265 A ZA200209265 A ZA 200209265A ZA 200209265 B ZA200209265 B ZA 200209265B
Authority
ZA
South Africa
Prior art keywords
antithrombotic agents
fixabs
suk
streptokinase
urokinase
Prior art date
Application number
ZA200209265A
Other languages
English (en)
Inventor
Frank C Barone
Michael N Blackburn
Giora Z Feuerstein
John R Toomey
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of ZA200209265B publication Critical patent/ZA200209265B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA200209265A 2000-05-15 2002-11-14 Antithrombotic agents. ZA200209265B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57143400A 2000-05-15 2000-05-15

Publications (1)

Publication Number Publication Date
ZA200209265B true ZA200209265B (en) 2003-10-22

Family

ID=24283688

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200209265A ZA200209265B (en) 2000-05-15 2002-11-14 Antithrombotic agents.

Country Status (20)

Country Link
US (1) US20050037006A1 (zh)
EP (2) EP1282444B1 (zh)
JP (1) JP2004516236A (zh)
KR (2) KR20030034071A (zh)
CN (2) CN101134107A (zh)
AT (1) ATE345816T1 (zh)
AU (2) AU7858400A (zh)
BR (1) BR0015872A (zh)
CA (1) CA2411369A1 (zh)
CZ (1) CZ20023778A3 (zh)
DE (1) DE60032029T2 (zh)
ES (1) ES2277597T3 (zh)
HU (1) HU225874B1 (zh)
IL (1) IL152831A0 (zh)
MX (1) MXPA02011385A (zh)
NO (1) NO20025463L (zh)
NZ (1) NZ522632A (zh)
PL (1) PL360060A1 (zh)
WO (1) WO2001087339A1 (zh)
ZA (1) ZA200209265B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
ES2436467T3 (es) 2002-03-20 2014-01-02 University Of Maryland Baltimore Un canal catiónico no selectivo en células neurales y antagonistas de Sur1 para el tratamiento de la inflamación del cerebro
ATE487484T1 (de) 2004-09-18 2010-11-15 Univ Maryland Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
AU2005290238A1 (en) * 2004-09-18 2006-04-06 Department Of Veterans Affairs Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
US8236316B2 (en) * 2007-11-21 2012-08-07 Oregon Health & Science University Anti-factor XI monoclonal antibodies and methods of use thereof
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
WO2018116267A2 (en) * 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
WO2018199214A1 (ja) 2017-04-27 2018-11-01 中外製薬株式会社 薬物動態が改善された血液凝固第ｉｘ因子
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
JP4638035B2 (ja) * 1998-08-28 2011-02-23 ジェネンテック， インコーポレイテッド ヒト抗−ＩＸ／ＩＸａ因子抗体

Also Published As

Publication number Publication date
CN1501812A (zh) 2004-06-02
BR0015872A (pt) 2004-08-03
KR20070116192A (ko) 2007-12-06
HU225874B1 (en) 2007-11-28
HUP0301804A3 (en) 2005-12-28
IL152831A0 (en) 2003-06-24
WO2001087339A1 (en) 2001-11-22
ATE345816T1 (de) 2006-12-15
JP2004516236A (ja) 2004-06-03
PL360060A1 (en) 2004-09-06
DE60032029D1 (de) 2007-01-04
CN101134107A (zh) 2008-03-05
HUP0301804A2 (hu) 2003-08-28
NO20025463L (no) 2003-01-09
EP1282444A4 (en) 2004-06-30
EP1825864A3 (en) 2007-09-12
CN100339132C (zh) 2007-09-26
NO20025463D0 (no) 2002-11-14
AU7858400A (en) 2001-11-26
MXPA02011385A (es) 2004-01-26
EP1825864A2 (en) 2007-08-29
EP1282444A1 (en) 2003-02-12
EP1282444B1 (en) 2006-11-22
US20050037006A1 (en) 2005-02-17
CA2411369A1 (en) 2001-11-22
AU2000278584B2 (en) 2006-11-16
ES2277597T3 (es) 2007-07-16
KR20030034071A (ko) 2003-05-01
NZ522632A (en) 2005-05-27
DE60032029T2 (de) 2007-05-31
CZ20023778A3 (cs) 2003-08-13

Similar Documents

Publication Publication Date Title
BE2013C050I2 (zh)
ZA200209265B (en) Antithrombotic agents.
PL350042A1 (en) Serine protease inhibitors
WO2002095007A3 (en) Conjugates activated by cell surface proteases and therapeutic uses thereof
AU6379101A (en) Highly selective inhibitors of the urokinase plasminogen activator
NO941561L (no) Bifunksjonelle urokinasevarianter med forbedrede fibrinolytiske egenskaper og trombinhemmende virkning
ZA887556B (en) Modified tissue plasminogen activator
DE59001558D1 (de) Thrombolytisch wirkendes kombinationspraeparat.
AU2002320150A1 (en) Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent
AU2002255784A1 (en) Antisense modulation of urokinase plasminogen activator expression